Safety, Pharmacokinetics, and Activity of the Anti-NaPi2b Antibody-Drug Conjugate DNIB0600A: A Phase I Study in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Gerber De, HA Burris, Lin Kang(Nanjing Medical University), Junying Xu(Wuxi People's Hospital), David R. Spigel(Sarah Cannon), Robert S. Kahn(University of California, Los Angeles), Infante

Unknown

January 1, 2013

Cited by 2

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

|New England Journal of Medicine|2012|12.6k

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

|Annals of Oncology|2020|1.5k

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2015|1.2k

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

|The Lancet Oncology|2019|564

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

|Journal of Clinical Oncology|2012|373